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The simian human immunodeficiency virus (SHIV) macaque model of AIDS has provided a very useful system for
evaluation of envelope-based candidate vaccines against HIV-1. Eight rhesus macaques were immunized with monomeric
recombinant gp120 of HIV-1LAI (rgp120) and used to evaluate whether this vaccine conferred protection against challenge
with pathogenic SHIVs (SHIVKU-2 and SHIV89.6P). The vaccinated macaques developed high titers of antibodies against rgp120
that reacted efficiently with the envelope proteins of homologous SHIV (SHIVKU-2) and poorly with the SHIV89.6P envelope, a
heterologous strain of SHIV. This vaccine also induced neutralizing antibodies but only against SHIVKU-2. Vaccine-induced
antibodies were of high avidity and predominantly against linear epitopes on the protein. Vaccinated macaques developed
gp120-specific T-helper cells but no consistent cytotoxic T lymphocytes. However, cellular immune responses were
short-lived in all eight vaccinates. At week 22 postimmunization, four vaccinates were challenged with SHIVKU-2 and the other
four with SHIV89.6P. Four unvaccinated control macaques were also infected: two with SHIVKU-2 and two with SHIV89.6P.
Vaccinated macaques generally showed anamnestic antibody and T-helper cell responses. However, T-helper responses
were again short-lived. Upon challenge, the level of productive virus replication was indistinguishable between vaccine and
control groups, suggesting that rgp120 did not confer protection against virus replication when animals were challenged with
homologous or heterologous SHIV viruses. © 2000 Academic PressINTRODUCTION
The envelope protein gp120 of HIV-1 has received
great attention for use as a possible vaccine against this
virus because it contains epitopes that bind receptors on
host cells (Wyatt, 1998; Kwong, 1998; Rizzuto et al., 1998;
Wang, 1998; Ross and Cullen, 1998; Misse et al., 1998),
epitopes that induce neutralizing antibodies (Berman et
al., 1992; Hansen et al., 1992; Bruck et al., 1994; Trkola et
al., 1996; Burton, 1997; Beddows et al., 1999), and other
epitopes that elicit cell-mediated immune responses
(Wiseman et al., 1991; Berggren et al., 1995; Kahn et al.,
1995; McElrath et al., 1996; Mooij et al., 1998). Moreover,
the availability of this antigen as a recombinant protein
offers an advantage over other candidate vaccines (Gra-
ham and Wright, 1995; Mascola et al., 1996; Graham et
al., 1996; Corey et al., 1998; Connor et al., 1998). While
these are major factors that have favored the utilization
of this molecule for clinical studies, it is still not known
with certainty whether a gp120 vaccine could induce
protection against HIV infection or, failing this, prevention
of disease (McElrath et al., 1996; Connor et al., 1998). The
breadth of the protection against heterologous viruses
1 To whom correspondence and reprint requests should be ad-
ressed. Fax: (913) 588-5599. E-mail: Akumar@kumc.edu.
149(Berman et al., 1992; Graham and Wright, 1995; Mascola
et al., 1996) and the duration of the induced protection
following immunization also remain unknown (McElrath
et al., 1996).
Evaluation of the efficacy of the gp120 vaccine that is
currently in clinical trials is difficult to assess, since
defintive immunological correlates of protection against
HIV-1 are not known. Furthermore, the protective efficacy
of the gp120 vaccine would be difficult to assess in
clinical trials because of the variability in exposure to
infection and the prolonged incubation period among
different individuals. It is already known that recombinant
gp120 protein does not induce consistent cytotoxic T-
lymphocyte (CTL) responses and in a study wherein
recombinant protein was used for immunization, only
one of 13 volunteers developed envelope-specific CTLs
(Graham et al., 1996). However, in another prime–boost
study in which 56 volunteers were primed with recombi-
nant vaccinia virus expressing gp160 of LAI isolate and
boosted with recombinant protein, approximately 50%
volunteers developed envelope-specific CTLs (Corey et
al., 1998). Reports have already started coming out from
different clinical trials that some individuals immunized
with this vaccine have become infected following expo-
sure to the virus (McElrath et al., 1996; Connor et al.,
1998).
0042-6822/00 $35.00
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150 KUMAR ET AL.Attempts to determine the efficacy of gp120 vaccines
in chimpanzees have not been completely satisfactory
because of the limited numbers of animals in trials and
the problem that chimpanzees are poorly susceptible to
infection with HIV-1 (Bruck et al., 1994; Berman et al.,
1990; Girard et al., 1991; Lubeck et al., 1997). However,
recent derivations of pathogenic simian human immuno-
deficiency viruses (SHIVs) offer an alternate animal
model to evaluate the efficacy of this vaccine in ma-
caques. These pathogenic viruses cause an acute dis-
ease in macaques characterized by high virus burdens in
plasma, rapid loss of CD41 T cells, and onset of AIDS
ithin 8 months (Luciw et al., 1995; Joag et al., 1996;
eimann et al., 1996a,b; Joag et al., 1997,1998a; Steger et
al., 1998; Igarashi et al., 1999). Pretreatment of macaques
ith neutralizing antibodies conferred protection against
nfection with pathogenic SHIV (Foresman et al., 1998;
hibata et al., 1999; Mascola et al., 1999). This is similar
o results obtained in chimpanzees, in which pretreat-
ent of animals with anti-HIV neutralizing antibodies
revented infection with HIV-1 (Emini et al., 1992).
In this study, we evaluated the efficacy of recombinant
p120 (rgp120) in rhesus macaques against SHIVKU-2 and
HIV89.6P infection. Eight rhesus macaques were immu-
ized three times with gp120 and followed for develop-
ent of gp120-specific cellular and humoral immune
esponses. Twelve weeks after the last injection, four
accinates and two controls were challenged with
HIVKU-2 and another group of four vaccinates and two
controls was challenged with SHIV89.6P.
RESULTS
Eight rhesus macaques were immunized three times
with rgp120 (HIV-1LAI). Each animal received 100 mg
rgp120 emulsified in Freund’s complete adjuvant and
was subsequently boosted at weeks 3 and 10 with 50 mg
of rgp120 in Freund’s incomplete adjuvant. At week 22,
four vaccinates (47/A, 47/B, 47/C, and 47/D) were chal-
lenged with SHIVKU-2 and the other four vaccinates (47/E,
47/F, 47/G, and 47/H) were challenged with SHIV89.6P.
Two unvaccinated macaques (48/T1 and 48/T2) were
inoculated with SHIVKU-2, and two (49/P1 and 49/P2) were
inoculated with SHIV89.6P.
Vaccinated macaques developed high levels of anti-
gp120 antibodies that bound to the SHIV envelope
glycoprotein
Plasma samples collected at 10 intervals between
weeks 4 and 34 from eight vaccinated animals were
examined for the presence of binding antibodies to
rgp120 and whether those antibodies cross-reacted with
envelope proteins of SHIVKU-2 and SHIV89.6P. The gp120-
pecific antibody titers were determined in a standard
LISA and antibody titers against the envelope protein of
he two SHIV viruses were determined in a concanavalin
t
s(Con A) ELISA. The results of these experiments are
hown in Fig. 1. All eight vaccinates developed gp120-
pecific antibodies. The antibody titer ranged between
000 and 64,000 at week 4 when we first determined the
ntibody levels in eight vaccinated animals. The antibody
evels increased substantially after the second boost,
ttaining peak levels within 1–6 weeks after injection.
he peak anti-gp120 antibody titers ranged between
28,000 and 1,024,000. The antibody titers gradually de-
lined afterward and ranged between 32,000 and
28,000 at week 12 postimmunization when the animals
ere challenged with pathogenic SHIV. The animals de-
eloped anamnestic responses and the levels of anti-
p120 antibody increased in seven vaccinates. However,
ntibody levels declined slightly in five of eight vacci-
ated macaques within 12 weeks after challenge. These
p120-specific antibodies cross-reacted with the enve-
ope of SHIVKU-2 very efficiently, confirming the close
antigenic relationship between HIV-1LAI and IIIB (the en-
velope of SHIVKU-2 was derived from HIV-1IIIB). These
antibodies cross-reacted with the envelope of SHIV89.6P
at least 30 times less efficiently, confirming the antigenic
disparity between HIV-1IIIB and SHIV89.6P. At the time of
hallenge all four animals challenged with SHIVKU-2 had
antibody titers of at least 1/10,000 against the envelope
of the challenge virus. However, three of the four animals
challenged with SHIV89.6P had no detectable antibodies
directed against the envelope of the challenge virus.
Peripheral blood mononuclear cells (PBMCs) from these
animals were used to quantify antibody-secreting cells
(ASC) in ELISPOT assays. All animals showed ASC spe-
cific to rgp120 that generally increased after the second
boost. However, no direct correlation was observed be-
tween antibody titers and ASC numbers (Table 1).
The unvaccinated control animals were also moni-
tored for the development of binding antibodies against
monomeric recombinant gp120 following challenge. The
results of this experiment are illustrated in Fig. 2A. The
two animals (49/P1 and 49/P2) inoculated with SHIV89.6P
id not develop detectable antibodies. However, the two
nimals inoculated with SHIVKU-2 developed detectable
ntibodies at week 6 that increased to titers of 4000 in
oth macaques.
accinated macaques produced high-avidity
ntibodies that were directed predominantly against
inear epitopes on the protein
Using monomeric and denatured rgp120, we analyzed
lasma samples collected at weeks 4, 11, and 24 for the
resence of antibodies to conformation-dependent
pitopes on gp120. Antibody avidity was determined by
easuring the resistance of antigen–antibody com-
lexes to denaturation with 8 M urea. Table 2 presents
he results of these experiments. One week after the
econd rgp120 injection (week 4), antibodies in five of
A
2
(
151gp120 VACCINATION IN SHIV/RHESUS MODELFIG. 1. Evolution of binding antibody responses in gp120 vaccinates. Eight rhesus macaques were primed and boosted with rgp120 at weeks 0,
3, and 10. At 22 weeks, four vaccinates (47/A, 47/B, 47/C, and 47/D) were challenged with SHIVKU-2 and four (47/E, 47/F, 47/G, and 47/H) with SHIV89.6P.
rrows in each figure indicate the time of vaccinations and challenge. Plasma samples were collected from each animal at weeks 4, 8, 11, 13, 17, 22,
4, 26, 30, and 34 and screened against rgp120 (}—}) in a standard ELISA, as well as against SHIVKU-2 envelope (t—t) and SHIV89.6P envelope
—) in Con A ELISA. Results are expressed as antibody titer.
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152 KUMAR ET AL.eight vaccinated macaques had avidities of 52.8 to 77.6%,
while three other vaccinates (47/E, 47/G, and 47/H) had
antibodies of intermediate avidity. The antibody avidity
index showed a steady increase in seven of eight mon-
keys after the third gp120 injection and ranged between
73.7 and 88.6%. The eighth macaque (47/A) developed
highly avid antibodies after the second gp120 injection
and did not show any change after the third injection.
The avidity indices remained high and did not show any
significant change after challenge with pathogenic
SHIVs. However, the conformation dependence of anti-
gp120 antibodies decreased over time. At week 4, seven
of eight vaccinated macaques produced approximately
25% of circulating anti-gp120 antibodies that were di-
rected against a conformation-dependent epitope(s) on
the protein. However, during the maturation process
these antibodies disappeared, and at week 11 postim-
munization, all vaccinates had antibodies only against a
linear epitope(s) on the protein. In the control group the
two macaques inoculated with SHIVKU-2 developed bind-
ng antibodies against gp120. The plasma samples from
hese animals were examined for antibody maturation.
FIG. 2. Evolution of binding (A) and neutralizing (B) antibodies in co
and 49/P2). The binding antibody titer was detected in ELISA using re
TABLE 1
Enumeration of gp120-Specific Antibody-Secreting Cells in PBMCs
of Vaccinated Animals
Macaque
Number of antibody-secreting cells/106 PBMCsa
Week 4 Week 11 Week 23
47/A 126 6 28 343 6 52 357 6 95
47/B 35 6 15 264 6 91 327 6 115
47/C 98 6 29 308 6 50 443 6 91
47/D 133 6 44 380 6 50 510 6 67
47/E 35 6 12 391 6 23 713 6 81
47/F 76 6 33 484 6 142 338 6 53
47/G 68 6 28 342 6 179 401 6 46
47/H 174 6 70 427 6 16 710 6 103
a 105, 5 3 104, and 2.5 3 104 PBMCs were added in quadruplicate
rgp120-coated HA plates. The cells were incubated for 5 h and the
assay was performed as described under Materials and Methods. The
numbers of antibody-secreting B cells are presented per 106 PBMCs 6
SD.against challenge virus as described in Materials and Methods. Each plasma
are expressed as the reciprocal of the highest dilution that arrested cytopathhe results of this experiment are shown in Table 3. Both
nimals had a majority of antibodies that were directed
o a conformation-dependent epitope(s) on the gp120
rotein, and these antibodies remained of low avidity
uring the 12-week observation period.
p120 vaccination induced moderate levels of
eutralizing antibodies against SHIVKU-2 but none
gainst SHIV89.6P
Anti-gp120 antibodies produced in response to the
vaccine did not neutralize SHIV89.6P. However, plasma
from seven of the eight vaccinates neutralized SHIVKU-2 at
titers of 35 to 80. These antibodies disappeared gradu-
ally and at week 22 postimmunization, none of the eight
vaccinates had detectable neutralizing antibodies
against SHIVKU-2 (Fig. 3). However, all eight vaccinated
nimals developed a dramatic increase in the levels of
HIVKU-2-specific neutralizing antibodies after challenge,
irrespective of whether the animals were challenged
with SHIVKU-2 or SHIV89.6P. The levels of neutralizing anti-
odies reached a maximum between weeks 24 and 28
ostvaccination (titers 70–240) and then declined sharply
nd became undetectable by week 30 (week 8 postchal-
enge). Following challenge with either pathogenic SHIV,
our vaccinated animals developed low levels of anti-
HIV89.6P neutralizing antibodies (antibody titers: 5 in
7/A and 47/B; 10 in 47/C and 47/E). The two SHIV89.6P
ontrol animals (49/P1 and 49/P2) did not develop neu-
ralizing antibodies against challenge virus. However,
wo SHIVKU-2 controls (48/T1 and 48/T2) developed low
evels of neutralizing antibodies (titer 10) at week 11
ostinfection when 8 TCID50 of SHIVKU-2 was used for the
neutralization assay (Fig. 2B).
Cellular immune response in vaccinated animals
PBMCs from vaccinated macaques proliferated in re-
sponse to rgp120. All eight vaccinated macaques were
monitored for the development of rgp120-specific prolif-
erative responses. As shown in Fig. 4, all eight vacci-
nates primed gp120-specific T cells after the first injec-
tion, and this response was boosted in all animals after
the second injection, reaching peak values at week 6
acaques infected with SHIVKU-2 (48/T1 and 48/T2) and SHIV89.6P (49/P1
ant gp120 as antigen. The neutralizing antibody titers were detectedntrol m
combinsample was tested in quadruplicate and neutralization end-point titers
ic effect.
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153gp120 VACCINATION IN SHIV/RHESUS MODELpostimmunization. The response declined after week 6
and ranged between 1.2 and 10.8 at week 10 postimmu-
nization. The third injection resulted in a greater boosting
effect than the second injection, with the stimulation
index (SI) reaching between 22 and 37. However, this
response was transient and at the time of challenge,
stimulation indices had declined to low levels with stim-
ulation indices ranging from 3.5 to 7.8. After challenge
with pathogenic SHIV, six of the eight macaques (four
challenged with SHIVKU-2 and two with SHIV89.6P)
mounted anamnestic responses to gp120. However, this
response was also short-lived and declined to insignifi-
cant levels within the following 12 weeks. Two vacci-
nated macaques, challenged with SHIV89.6P, did not
ount anamnestic responses. Rather, SI values declined
teadily.
T
Characterization of gp120-Specific Antibody Respo
Challenged with
Macaquea
Avidity index (%)b
Week 4 Week 11 W
47/A 77.6 72.5
47/B 64.1 81.2
47/C 64.7 87.0
47/D 54.5 73.7
47/E 45.9 88.6
47/F 52.8 76.9
47/G 43.5 86.1
47/H 40.4 74.6
a Eight macaques were immunized and boosted with 100 and 50 mg
B, C, D) were challenged with SHIVKU-2 and four with SHIV89.6P.
b Avidity index was determined by measuring the relative stability of
(X) were calculated by dividing the absorbance obtained in urea-washe
resultant value by 100. The avidity of antibody was considered high if X
c Conformation dependence of antibody was determined by compar
TABLE 3
Characterization of gp120-Specific Antibody Response in Control
Macaques Inoculated with SHIVKU-2
Macaquea
Avidity index (%)b Conformational ratioc
Week 6 Week 11 Week 6 Week 11
48/T1 9.1 14.9 4.73 2.74
48/T2 8.2 15.7 4.23 2.22
a Two rhesus macaques were inoculated with SHIVKU-2, and plasma
was collected at weeks 6 and 11 postinfection.
b Avidity index was determined by measuring the relative stability of
the rgp120 antigen–antibody complexes to 8 M urea in ELISA. Avidity
indices (X) were calculated by dividing the absorbance obtained in
urea-washed wells by the absorbance obtained in PBS-washed wells
and multiplying the resultant value by 100.
c Conformation dependence of antibody was determined by compar-
ing reactivity with monomeric and denatured rgp120 in ELISA.After challenge with pathogenic SHIV, these animals
ere monitored for the presence of both gp120-specific
nd virus-specific T-helper responses. The responses
ere monitored once every week and peak stimulation
ndices are shown in Fig. 5. PBMCs from all eight vac-
inates proliferated in response to heat-inactivated chal-
enge virus. The stimulation indices obtained in response
o viral antigens were relatively low compared with those
btained in response to gp120 stimulation. In most of the
nimals, challenge virus-specific T-helper responses
eaked between weeks 2 and 4 postchallenge. The only
xceptions were 47/A and 47/C; these animals showed
aximum proliferative responses 12 weeks after chal-
enge. None of the unvaccinated controls, inoculated
ith either SHIVKU-2 or SHIV89.6P, developed significant
irus-specific Th responses.
gp120 immunization did not induce CTLs in rhesus
acaques. The vaccinated animals were monitored for
TL activity at weeks 11 and 12 postimmunization and at
eeks 1, 6, and 12 postchallenge (weeks 23, 28, and 34
ostimmunization, respectively). The PBMC effectors
ere tested against rVV-HIV-1ENV, B-lymphoblastoid cell
ines (B-LCLs) pulsed with rgp120, and autologous CD41
T cells infected with challenge virus at different effector/
target (E/T) ratios ranging from 5/1 to 80/1. The results of
CTL assays obtained with an E/T ratio of 40/1 are shown
in Table 4. At week 12 postvaccination, three animals
(47/C, 47/E, and 47/F) exhibited low CTL activity. How-
ever, this activity was not consistent, as none of these
animals showed specific lysis in the following weeks. As
a positive control for these studies we used PBMCs from
a macaque, PWv, that was immunized with live virus
Vaccinated Macaques Immunized with rgp120 and
U-2 and SHIV89.6P
Conformational ratioc
4 Week 4 Week 11 Week 24
1.28 1.02 1.00
1.07 1.04 1.04
1.40 1.10 1.04
1.29 1.01 1.04
1.39 1.08 1.01
1.44 1.05 1.01
1.45 1.06 1.03
1.41 1.02 1.06
at weeks 0, 3, and 10, respectively. At week 22, four macaques (47/A,
120 antigen–antibody complexes to 8 M urea in ELISA. Avidity indices
by the absorbance obtained in PBS-washed wells and multiplying the
50%, moderate if X was between 30 and 50%, and low if X was #30%.
ctivity with monomeric and denatured rgp120 in ELISA.ABLE 2
nse in
SHIVK
eek 2
75.9
73.1
86.2
67.2
79.5
82.9
81.6
67.9
rgp120
the rgp
d wellsvaccine (DvpuSHIVPPC) and subsequently resisted chal-
lenge with pathogenic SHIVKU (Joag et al., 1998b). The
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154 KUMAR ET AL.PBMCs from this animal were in vitro stimulated with
autologous HVS-immortalized CD41 T cells infected with
SHIVKU after UV irradiation and tested in a
51Cr-release
ssay. The effectors were tested against virus-infected
D41 T cells, and autologous B cells infected with re-
combinant vaccinia virus expressing HIV-1ENV, SIVGAG,
nd SIVPOL. The results of this experiment are shown in
Fig. 6. The PBMCs from this animal had CTL activities
against virus-infected targets as well as targets infected
with recombinant vaccinia viruses expressing HIV-1ENV,
SIVGAG and SIVPOL.
Clinical outcome of challenge with pathogenic SHIV
FIG. 3. Evolution of neutralizing antibody responses in gp120 vaccina
0, 3, and 10. At 22 weeks, four vaccinates (47/A, 47/B, 47/C, and 47/D
HIV89.6P. The time of vaccinations and challenge are indicated by arrow
for the ability of the samples to neutralize SHIVKU-2 (}—}) and SHIV89.6
quadruplicate and neutralization end-point titers are expressed as theSHIVKU-2 group. Four vaccinated (47/A, 47/B, 47/C,
and 47/D) and two control (48/T1 and 48/T2) animalswere inoculated with SHIVKU-2 virus. CD4 profiles, cell-
ssociated viral burdens, and plasma viral loads in
hese animals are shown in Figs. 7A, 7C, and 7E,
espectively. All six animals underwent massive loss
f CD41 T cells during the first 3 weeks following
hallenge. The severity of loss in CD41 T cells was
indistinguishable between vaccinates and controls.
The maximal CD41 T cell loss in vaccinated animals
as 89% in 47/A, 56% in 47/B, 72% in 47/C, and 92% in
7/D. The control animals 48/T1 and 48/T2 showed 97
nd 88% loss of CD41 T-cell populations, respectively
Fig. 7A). Although all animals, including controls,
howed a recovery in the levels of CD41 T-cell counts,
ght rhesus macaques were primed and boosted with rgp120 at weeks
challenged with SHIVKU-2 and four (47/E, 47/F, 47/G, and 47/H) with
ch figure. Serial dilution of heat-inactivated plasma samples was tested
t) in a 7-day neutralization assay. Each plasma sample was tested in
cal of the highest dilution that arrested cytopathic effect.tes. Ei
) were
s in eathis was more apparent in vaccinated animals. In
these animals, CD41 T-cell levels rebounded to at
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155gp120 VACCINATION IN SHIV/RHESUS MODELleast 50% of the prechallenge levels; however, one
vaccinate (47/D) recovered to the prechallenge level.
The level of productive virus replication, as determined
by infectious cell assay (Fig. 7C) and real-time RT-PCR
(Fig. 7E), was indistinguishable between the vaccine and
the control groups. The peak viral burdens were ob-
served 2 weeks after challenge and declined thereafter.
Peak plasma viral burden was 20–170 3 106 RNA
opy/ml in vaccinates, while the control animals showed
eak plasma viral burdens of 1.4 3 106 and 4 3 108 RNA
copy/ml. The reduction in plasma viral burden was also
similar between vaccine and control groups. The plasma
FIG. 4. Evolution of gp120-specific T-helper cells in macaques imm
primed and boosted with rgp120 at weeks 0, 3, and 10. They were s
SHIV89.6P (47/E, 47/F, 47/G, and 47/H). Monkeys were bled at different tim
proliferative responses in a 6-day thymidine incorporation assay. Resul
from rgp120-stimulated wells with mean cpm from wells that did not rviral burden became undetectable in two vaccinates and
one control 12 weeks after challenge.SHIV89.6P group. Four vaccinated (47/E, 47/F, 47/G,
nd 47/H) and two control (49/P1 and 49/P2) animals
ere inoculated with SHIV89.6P virus. CD4 profiles,
ell-associated viral burdens, and plasma viral loads
n these animals are shown in Figs. 7B, 7D, and 7F,
espectively. All six animals experienced a massive
oss of CD41 T cells. However, two of the vaccinated
nimals (47/E and 47/H) showed a remarkable recov-
ry. Macaque 47/E lost more than 80% of its CD41 T
cells within 1 week after infection, but its CD41 T-cell
counts recovered to the prechallenge level in the fol-
lowing week. This animal underwent another round of
1
and boosted with recombinant gp120. Eight rhesus macaques were
ently challenged with either SHIVKU-2 (47/A, 47/B, 47/C, and 47/D) or
ts (indicated on the X-axis), and PBMCs were tested for gp120-specific
xpressed as stimulation indices calculated by dividing the mean cpm
rgp120.unized
ubsequ
e poinCD4 T-cell loss, but this loss was also transient. At
week 12 this animal had CD41 T-cell counts similar to
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156 KUMAR ET AL.the prechallenge level. Macaque 47/H lost approxi-
mately 30% of its CD41 T cells, followed by a recovery
to the prechallenge level. The other two vaccinates
(47/F and 47/G) and two controls (49/P1 and 49/P2) did
not show any recovery in the number of CD41 T cells.
The levels of viral replication, as measured by ICA and
lasma viral load, were comparable in the vaccine and
ontrol groups. In three vaccinates and two controls,
irus levels were high throughout the observation period.
owever, one vaccinate (47/E) exhibited massive virus
eplication at week 1 postchallenge, but virus replication
as suppressed in the following weeks and plasma viral
oad became undetectable by week 12.
FIG. 5. Development of virus-specific T-helper cells in gp120 vacc
SHIV89.6P. Animals were bled every week for 12 weeks after challenge a
irus. The proliferative responses were examined every week in a 6-da
or each animal. The number in the “week” column denotes the time (
T
Lack of Consistent CTL Activity in Eight Vaccinated
Macaque Week 11b Week 12c
47/A 0 0
47/B 0 0
47/C 0 10.6
47/D 0 5.2 f
47/E 0 8.6
47/F 0 4.4
47/G 0 0
47/H 0 10.8 f
a Specific lysis was tested in a 4-h chromium-release assay. Effectors
epresent only the effector/target ratio of 40/1.
b Autologous B-LCLs, infected with HIV-1env, were used as target.
c Autologous B-LCLs, pulsed with rgp120, were used as target.
d Autologous CD41 T-cell clones, infected with SHIVKU-2 or SHIV89.6P,
e Mean spontaneous release in this assay was between 111 and 395 and
f Not significant. Difference between specific and nonspecific lysis was lesDISCUSSION
Recombinant gp120 has been evaluated in phase I
nd II clinical trials and found to be safe and immuno-
enic (Walker and Fast, 1994; Kahn et al., 1995; Connor et
al., 1998). These clinical trials were undertaken only to
determine the safety and immunogenicity of gp120 and
not to evaluate the ability of the vaccine to confer pro-
tection. However, several individuals participating in the
clinical trials became infected, indicating that the rgp120
vaccine conferred less than complete protection (Connor
et al., 1998). The early impetus for use of rgp120 as a
possible vaccine against HIV-1 came from several stud-
and control macaques that were challenged with either SHIVKU-2, or
PBMCs were stimulated with 20 ml UV-irradiated and heat-inactivated
idine incorporation assays. However, only peak responses are shown
llenge) when an animal had maximum proliferative response.
s Macaques Challenged with SHIVKU-2 or SHIV89.6P
entage specific lysisa
Week 23d,e Week 28d Week 34d
6.6 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
3.5 0 0
ested at E/T ratios of 80/1, 40/1, 20/1, 10/1, and 5/1. Results shown here
sed as target.inated
nd 105ABLE 4
Rhesu
Perc
were t
were u
mean maximal release ranged from 543 to 2327.
s than twofold.
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157gp120 VACCINATION IN SHIV/RHESUS MODELies in which rgp120-immunized chimpanzees were pro-
tected against challenge with HIV-1LAI and HIV-1SF2 (Ber-
man et al., 1990,1996; Girard et al., 1991,1995; Bruck et al.,
1994). However, the observations from these studies
were equivocal because of the small number of animals
used in the study and also because the strain of HIV-1
replicated poorly and rarely induced disease in chimpan-
zees (Letvin, 1998). Furthermore, in another study, immu-
nization with rgp120 failed to protect chimpanzees
against HIV-1 challenge (Warren and Levinson, 1995).
Unlike the data from the HIV-1/chimpanzee studies, en-
velope proteins from SIVmac, FIV, and EIAV failed to confer
rotection after challenge with the respective virus (Issel
t al., 1992; Daniel et al., 1994). However, protection was
chieved in a study in which animals were immunized
ith recombinant vaccinia virus expressing SIVgp160
nd challenged with a closely related virus (Hu et al.,
992). In a recent study, immunization with rgp120 from
IV-1SF-2 conferred a significant level of protection in
monkeys immunized with this protein and challenged
with SHIVSF13 (Verschoor et al., 1999). In another study,
tott et al. (1998) showed that rgp120 from the W61D
solate of HIV-1 failed to protect macaques against in-
ection with SHIVSF33. In view of such contradictory find-
ngs between the chimpanzee and the macaque models
n the efficacy of recombinant envelope proteins as
andidate vaccine, we immunized rhesus macaques
ith rgp120 (HIV-1LAI) and challenged them with patho-
genic SHIV to determine the efficacy of this vaccine in a
SHIV/rhesus model.
The original criteria for testing rgp120 as a candidate
vaccine were based on the assumption that neutralizing
FIG. 6. CTL activity in a macaque (PWv) immunized with a live
attenuated virus vaccine and challenged with pathogenic SHIVKU. At
eek 45 postchallenge, PBMCs were stimulated in vitro with UV-
rradiated autologous CD41 T cells infected with SHIVKU. The growing
BMCs were used as CTL effectors in a 4-h chromium-release assay
nd tested against mock-infected T cells, B-LCLs infected with wild-
ype vaccinia and recombinant vaccinia expressing HIV-1ENV, SIVGAG,
and SIVPOL. The CTL activity shown here is the specific lysis obtained
t an effector/target ratio of 40/1. The mean spontaneous release in this
ssay was between 155 and 287 and the mean maximal release was
etween 762 and 1031.antibodies were likely correlates of the protection
against HIV-1 and most of the HIV-1 neutralizing antibod-ies were directed against this protein (Hansen et al.,
1992; Moore and Ho, 1995). In view of such presumption
that anti-gp120 antibodies might play an important role,
our efforts were focused on characterization of the anti-
body responses to gp120. The vaccine used in this ex-
periment was clearly immunogenic. All eight animals
immunized with rgp120 developed high levels of binding
antibodies against the vaccine and the antibodies cross-
reacted with the envelope of the homologous SHIV (Fig.
1). The antibody response was boosted after challenge
with live virus, similar to results seen in clinical trials
(Connor et al., 1998). However, the response was rela-
tively type restricted. Anti-gp120 antibodies reacted with
the envelope of homologous SHIVKU-2. The envelope of
SHIVKU-2 is derived from HIV-1IIIB, but underwent several
utations during adaptation of nonpathogenic SHIV-4
nto pathogenic SHIVKU-2 (McCormick-Davis et al., 1998).
he type specificity of the gp120-specific immune re-
ponse was further confirmed by the finding that despite
high degree of homology, these antibodies cross-re-
cted poorly with the SHIV89.6P envelope (81.14% homol-
ogy with HIV-1LAI and 81.93% homology with SHIVKU-2 in
gp120 sequence).
All vaccinated animals developed antibodies that neu-
tralized SHIVKU-2 but only after the third injection. These
neutralizing antibodies were directed against a linear
epitope(s) on the protein as evidenced by the lack of
neutralizing capability at early time points. This was
further corroborated by our observation that when neu-
tralizing antibodies appeared in the circulation, the ani-
mals had antibodies against a linear epitope(s) but not
against a conformation-dependent epitope(s) on gp120.
We also observed a significant increase in the number of
gp120 antibody-secreting cells after the first and second
boosts. However, an increase in the ASC numbers upon
challenge was apparent in only two animals that were
challenged with SHIV89.6P. We could not find a correlation
between the number of the antibody-secreting cells and
the antibody titer. This lack of correlation suggests that
there may be other components involved in the final
outcome of antibody responses.
The maturation process of the gp120-specific antibod-
ies seems to be different from those reported earlier in
SIV- or SHIV-infected macqaues. It has been shown by
several groups that envelope-specific antibodies mature
slowly and require several months before developing
into highly avid antibodies (Clements et al., 1995; Cole et
l., 1997a,b, 1998). In the present study, two control ani-
als that were infected with SHIVKU-2, exhibited a pattern
of slow maturation, and during the 12-week observation
period these antibodies were predominantly targeted to
a conformation-dependent epitope(s) on the protein.
These antibodies were of lower avidity, similar to those
reported previously (Cole et al., 1997b,1998). In contrast,
in the vaccinated group reported here, antibody matura-
tion was swift in all animals. Further, these animals
ined by
(
158 KUMAR ET AL.required only a few weeks for development of highly avid
antibodies. This discrepancy in antibody maturation in
FIG. 7. Clinical outcome of challenge of gp120 vaccinates with SHIV
animals were challenged with SHIVKU-2 and another group of four vacci
animals and open symbols for control animals. The postchallenge CD4
of CD41 T cells/ml of blood. The cell-associated viral loads were mea
cells/106 PBMC (C and D). The viral RNA loads in plasma were determ
E and F).SHIV-infected animals and gp120-immunized animals
can be attributed to two possibilities. (i) These animals inthe latter group were immunized with a recombinant
protein and in a previous study it has been shown that
C, and E) and SHIV89.6P (B, D, and F). Four vaccinated and two control
nd two controls with SHIV89.6P. Solid symbols are used for vaccinated
[(A) SHIVKU-2 group and (B) SHIV89.6P group] are presented as numbers
in an infectious cell assay and are presented as numbers of infected
real-time RT-PCR and results are presented as viral RNA copy Eq/mlKU-2 (A,
nated a
profiles
suredrabbits immunized with recombinant gp160 protein de-
veloped highly avid antibodies within 4 weeks after prim-
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159gp120 VACCINATION IN SHIV/RHESUS MODELing that remained unchanged after boost (Richmond et
al., 1998). (ii) The macaques in the present study were
immunized with rgp120 using complete Freund’s adju-
vant (CFA) that has been shown to accelerate antibody
maturation in vaccinated animals (Levi et al., 1993).
Another remarkable finding of the study was our ob-
ervation that four vaccinated macaques (47/E, 47/F,
7/G, and 47/H), though challenged with SHIV89.6P, dis-
played increased neutralizing antibodies only against
SHIVKU-2 (Fig. 3). Three of the four macaques in this group
also exhibited elevated levels of binding antibodies
against the SHIVKU-2 envelope. However, an increase in
inding antibody levels was less apparent than the in-
rease in the levels of neutralizing antibody. This phe-
omenon, “original antigenic sin,” has been used to ex-
lain the antibody response to influenza virus (Webester,
966; Fazekas and Webster, 1966). Klenerman and Zink-
rnagel (1998) extended the concept of original antigenic
in to the CTL responses in the LCMV system.
Our results clearly demonstrated that the gp120 pro-
ein was able to prime T-helper cells, which probably
elped B cells to produce antibodies. However, vacci-
ated macaques lost the majority of CD41 T cells after
challenge with a heterologous strain of virus (SHIV89.6P),
and thus they had no chance to develop newly primed
CD41 T cells. However, some of the previously primed T
cells perhaps underwent expansion and activated mem-
ory B cells, resulting in an anamnestic response to the
original immunogen. In view of these findings, the use of
recombinant vaccines should be pursued with caution
since they may induce antibodies to the immunogen but
not to the challenge virus where the critical epitope(s) is
different.
In the present study, vaccinated animals showed
gp120-specific proliferative responses, suggesting that
MHC class II-restricted T-helper cells may have been
expanded by the rgp120 vaccination. The ability of
rgp120 to induce the T-helper response has been re-
ported in several laboratories (Kahn et al., 1995; Stott and
lmond, 1995; Lekutis et al., 1997; Lekutis and Letvin,
998; Mellado et al., 1998). However, as observed in an
arlier study (Walker and Fast, 1994), T-cell proliferative
esponses were short-lived and declined below the level
f detection within 12 weeks after challenge.
Monomeric rgp120 is known to be a poor inducer of
TL responses, and these results were confirmed in the
resent study. The failure of this vaccine to prevent
eplication of the pathogenic virus might be attributed to
ack of CTL responses. In several previously reported
tudies from our laboratory and others, the protection in
he macaque model of AIDS has been shown to be
ssociated with the development of virus-specific CTLs
Joag et al., 1998b; Johnson and Desrosiers, 1998; John-
on et al., 1997, 1999). In another previously reported
tudy, the failure of gp120 to protect vaccinated individ-
als against infection has also been indirectly ascribedto the lack of these cells (Corey et al., 1998). However,
continuous examination of these animals for a longer
period will help to elucidate whether this vaccine has
some beneficial effect in delay of onset of clinical AIDS.
MATERIALS AND METHODS
Viruses, animals, and challenge stock
Twelve sexually mature rhesus macaques (Macaca
mullata) were obtained from the Yerkes Primate Center
(Atlanta, GA) and maintained in AA ALAC-approved ani-
mal facilities at the University of Kansas Medical Center.
The NIH guidelines were followed for maintenance and
research protocols. Prior to the experimental protocol,
the monkeys were quarantined for 6 weeks. During this
period, the animals received three tuberculin injections
and were monitored for hematological and clinical pa-
rameters. The animals were also screened for antibody
profiles against different viruses, including SIV and
STLV-1.
The development of pathogenic SHIVKU-2 has been
described (Joag et al., 1998a). SHIV89.6P was kindly pro-
ided by Dr. Norman Letvin (Boston, MA) (Reimann et al.,
996). These viruses were grown in PHA-stimulated rhe-
us PBMCs and titrated using C8166 cells. The titers of
he challenge virus stocks were 104.9 and 104.7 TCID50 for
HIVKU-2 and SHIV89.6P, respectively. Herpesvirus saimiri
as obtained from ATCC (Manassas, VA) and grown in
MK cells (ATCC). Herpesvirus papio stock was ob-
ained by growing the S594 cell line, which was gener-
usly provided by Dr. N. Letvin. This cell line is an
mmortalized B-cell line productively infected with the
aboon H. papio (Rabin et al., 1977). The recombinant
accinia viruses that were used to infect target cells
ncluded vAbT299 (expressing HIV-1BH-10ENV lacking 19
amino acids starting from position 42–60 at the amino
terminus), vAbT252 (SIVmac251-GAG), vAbT258R
(SIVmac251-POL), and NYCBH (wild-type vaccinia virus).
hese were kindly provided by Drs. D. Panicali and G.
azzara (Therion Biologics, Cambridge, MA). The re-
ombinant vaccinia virus stocks were propagated in
eLa cell culture. All virus stocks were maintained at
80°C except the challenge virus stock, which was
tored in liquid nitrogen.
mmunization of macaques with gp120 and challenge
ith pathogenic SHIV
Monomeric rgp120 of the LAI isolate of HIV-1 was
indly provided by Dr. Alan Schultz (NIH, Bethesda, MD).
he recombinant gp120 was commercially produced by
ntracel (Rockville, MD) by expressing HIV-1LAI gp120
DNA in CHO cells. The expression product was charac-
terized by Western blot assay using sheep antibody to
HIV-1 gp20 and sequencing. Purity of the recombinant
product was .98%.
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160 KUMAR ET AL.Eight rhesus macaques were immunized by the intra-
dermal route with 100 mg of rgp120 emulsified in CFA.
hey were boosted twice with 50 mg of rgp120 emulsified
n incomplete Freund’s adjuvant, at weeks 3 and 10.
welve weeks after the last immunization (week 22),
ach group of four vaccinated and two control macaques
as challenged intravenously with 1 ml of either SHIVKU-2
or SHIV89.6P. Complete Freund’s adjuvant was used in the
tudy because this adjuvant is one of the most potent of
ll available adjuvants.
rocessing of samples
Blood was obtained from the femoral vein using hep-
rin or ethylenediamine-tetraacetic acid (EDTA) as anti-
oagulants. The blood was centrifuged at 3000 rpm for
0 min and plasma was stored at 280°C. The EDTA
lasma was used for real-time RT-PCR and heparinized
lasma for the different antibody assays. The cells were
esuspended in Hank’s balanced salt solution (HBSS)
nd PBMCs were separated from cell suspension by
entrifugation through a Ficoll–Hypaque gradient. The
nterface containing PBMCs were harvested and sub-
ected to ammonium chloride lysis for removal of resid-
al red blood cells. The remaining cells were washed
wice with HBSS, resuspended in R-10 medium, and
sed for different experiments. This method of PBMC
urification typically provided a cell mononuclear cell
opulation that contained 52–60% CD31 T cells and
–12% CD201 B cells.
ymphocyte phenotyping
PBMCs were stained for lymphocyte surface markers
s reported previously (Joag et al., 1998a,b). Briefly, 5 3
05 PBMCs were stained for 60 min at 4°C with mouse
monoclonal antibodies to either CD4 or CD8 (Dako,
Carpinteria, CA). The cells were washed with cold phos-
phate-buffered saline (PBS) and incubated with fluores-
cein isothiocyanate-conjugated goat anti-mouse immu-
noglobulin G (Dako). The cells were washed again, fixed
in 1% buffered formalin, and analyzed on FACScalibur
flow cytometer (Becton Dickinson, Indianapolis, IN). The
absolute number of CD41 and CD81 T cells/ml of blood
as calculated by multiplying the percentage of each
ymphocyte subset and the absolute number of lympho-
ytes/ml from the complete blood count.
uantification of viral RNA in plasma and infectious
ell assay
Viral load in plasma was quantitated by real-time RT-
CR as described previously (Suryanarayana et al.,
998). Briefly, RNA was isolated from 500 ml plasma and
amplified using SIVgag primers. This assay has a nom-
inal threshold sensitivity of 300 copy Eq/ml of the plasma.
Infectious cell assays were performed by cocultivatingPBMCs with indicator cells as reported previously (Joag
et al., 1998a,b).
Determination of binding antibody titers
Plasma samples from vaccinated monkeys were an-
alyzed for their reactivity to native viral glycoprotein in
a Con A ELISA (Robinson et al., 1990). Triton X-100-
treated and density gradient-purified virus was used
as the source of viral antigen. Each well of Immulon II
microtiter plates (Dynatech Laboratories) was coated
with Con A and then incubated with viral proteins. The
plates were then blocked with RPMI 1640 containing
10% fetal bovine serum (FBS; R-10) for 1 h and sequen-
tial dilutions of plasma were added in duplicate. After
a 90-min incubation at 37°C, plates were washed
three times with normal saline Tween (NST; 0.85%
NaCl and 0.1% Tween 20). One hundred microliters of
peroxidase-conjugated anti-monkey IgG (Sigma), di-
luted 1:10,000 in PBS containing 1% FBS, was added to
each well. The plate was incubated at 37°C for 1 h,
followed by three washes with NST. The reaction was
developed with ortho-phenylinediamine, and optical
density (OD) was measured in a plate reader (Dyna-
tech) at 490-nm wavelength. End-point titers were cal-
culated from the last dilution whose OD was twice that
of normal monkey plasma at 1/1000 dilution or an OD
of 0.1, whichever value was greater.
Anti-gp120 antibodies were detected by coating 100
ng of rgp120 protein into each well of an Immulon II plate
in 100 ml PBS. After incubation for 3 h at 37°C, the
gp120-coated plates were blocked with PBS containing
3% bovine serum albumin. One hundred microliters of
serially diluted plasma was then added in duplicate and
plates were incubated for 90 min at 37°C. The plates
were washed, incubated with anti-monkey Immunoglob-
ulin-G labeled Horseradish Peroxidase (anti-monkey
IgG-HRP), and developed as described above for Con A
ELISA.
Measurement of conformational dependence of
antibodies
Antibodies from vaccinated macaques were analyzed
for their conformation dependence by comparing the
reactivity of the antibodies to monomeric and denatured
rgp120 in ELISA (Cole et al., 1997a,b). The denatured
gp120 was prepared by treating rgp120 with 0.12 M
2-mercaptoethanol and 8 M urea to reduce disulfide
bonds followed by treatment with iodoacetic acid to
irreversibly carboxymethylate the reduced sulfahydryl
groups. The denatured gp120 was then extensively dia-
lyzed against PBS and concentrated by spinning through
a Centricon filter. The protein concentration was deter-
mined using the Bio-Rad DC protein assay. The plasma
dilution that had an OD between 1 and 1.5 in gp120
ELISA was used in these experiments. The conforma-
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161gp120 VACCINATION IN SHIV/RHESUS MODELtional ratio was then calculated by dividing OD obtained
against monomeric rgp120 with OD obtained against
denatured rgp120.
Determination of antibody avidity
The avidity of envelope-specific antibodies was deter-
mined by measuring the resistance of the antigen–anti-
body complex to 8 M urea (Thomas and Morgan-Capner,
1991). A given plasma dilution with an OD between 1 and
1.5 against gp120 was tested in a standard ELISA in two
sets of triplicate wells. The only difference from standard
ELISA was that after plasma incubation, one set of three
wells was treated with 8 M urea for 5 min and then
washed four times with NST. The avidity index was cal-
culated from the ratio of the absorbance value obtained
with urea treatment to the absorbance value obtained
from untreated wells multiplied by 100. Antibodies with
an avidity index of ,30% were considered to be of low
avidity, those with values between 30 and 50% were
considered to be of intermediate avidity, and those with
values .50% were designated as high avidity.
ELISPOT assay for detection of gp120-specific
antibody-secreting B cells
The ELISPOT assay, developed by Taguchi et al.
(1990), was modified to detect gp120-specific B cells;
96-well mixed cellulose ester membrane HA plates (Mil-
lipore, Bedford, MA) were incubated overnight with 100
ng gp120 in 100 ml PBS, after which free binding sites
ere blocked with R-10. PBMCs (25,000) from different
accinated animals were added to each well of a HA
late in quadruplicate and the plate was incubated for
h in a CO2 incubator. After six washes with NST, the
lates were incubated first with biotinylated anti-human
gG–biotin followed by incubation with avidin–HRPO. The
p120-specific B cells were visualized by reaction with
EC and H2O2 in sodium acetate buffer. The granular red
spots, each representing a B cell, were counted using a
dissecting microscope.
Determination of neutralizing antibody titers
The neutralizing antibody titer in plasma was deter-
mined as described previously (Joag et al., 1998b).
Briefly, twofold serial dilutions of heat-inactivated plasma
in R-10 were prepared in quadruplicate in flat-bottom
96-well plates, and 16 TCID50 of the test virus (SHIVKU-2 or
HIV89.6P) was added to each well. Plates were incu-
ated for 1 h at 37°C and 104 C-8166 cells were added to
ach well. Each well was scored individually for the
irus-induced cytopathic effect after a 7-day incubation
t 37°C. The end-point titer was defined by the ability of
plasma dilution to neutralize the virus in all four wells.
s
tymphocyte proliferation assay
Sequential PBMC samples from different macaques
ere cultured at 105 cells/well in flat-bottom 96-well
tissue culture plates in 200 ml R-10. Twenty microliters of
SHIVKU-2 and SHIV89.6P stocks, UV-irradiated for 1 h and
heat-inactivated at 56°C for 3 h, were used as antigens.
Monomeric rgp120 was tested at 5 mg/ml. Three wells,
each containing no antigen, served as negative controls
for the experiments, and three other wells, stimulated
with 5 mg/ml of Con A, served as positive controls. Cells
ere cultured for 5 days and then pulsed with 1 mCi of
[3H]thymidine (sp act 247.9 GBq/mmol; NEN, Boston,
A). Eighteen hours after the addition of [3H]thymidine,
cells were harvested onto glass fiber filter mats using an
automated plate harvester (Skatron, Sterling, VA) and
[3H]thymidine incorporation was determined with a mi-
robeta liquid scintillation counter (Packard). The SI was
alculated as the mean counts per minute (cpm) in stim-
lated wells/mean cpm in negative control wells. A stim-
lation index of greater than 2.5 was considered signif-
cant (Buge et al., 1997).
Development of CD41 T-cell clones and B-cell line
CD41 T cells were negatively selected from PBMCs by
incubation of PBMCs with a mouse monoclonal antibody
against human CD8 that cross-reacts with macaque
CD8, followed by incubation with anti-mouse immuno-
globulin G-coated magnetic beads (Dynal, Lake Suc-
cess, NY). PBMCs enriched for CD41 T cells were then
inoculated with H. saimiri to generate immortalized T-cell
lines (Kumar et al., 1999). The CD41 T-cell clones were
eveloped by limiting dilution and characterized by stain-
ng with anti-human CD4 antibody. The clones were
aintained in R-10 containing 50 IU/ml of IL-2. Immortal-
zed B-cell lines were developed by infecting PBMCs
ith H. papio (Lekutis et al., 1997).
eneration of effector T-cell population and CTL
ssay
PBMCs from vaccinated macaques were cocultured in
-10 with UV-irradiated autologous H. saimiri trans-
ormed CD41 T cells infected with either SHIVKU-2 or
HIV89.6P (effector/stimulator ratio of 10/1). One week
fter the initial stimulation, PBMCs were restimulated as
escribed above, except that the medium was supple-
ented with recombinant interleukin-2 (rIL-2; 50 IU/ml).
ne week after the second stimulation, these cells were
sed as effectors in a 4-h chromium-release assay. Two
illion target cells (CD41 T cells infected with SHIVKU-2 or
HIV89.6P, B-LCL infected with rVV-HIVenv, or gp120
ulsed autologous B-LCL) were labeled with 100 mCi
51Cr-labeled sodium chromate (sp act 962 MBq/ml of
odium chromate; Amersham, Cleveland, OH) for 2 h and
hen washed three times with HBSS. Target cells (2500/
s
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162 KUMAR ET AL.well) were dispensed into 96-well V-bottom plates. Effec-
tor cells were tested in triplicate at E/T ratios of 80/1,
40/1, 20/1, 10/1, and 5/1. Chromium release was deter-
mined after a 4-h incubation at 37°C by counting 100 ml
of supernatant from each well in a gamma counter (Pack-
ard, Meriden, CT). Each experiment had three wells con-
taining only 2500 targets in the medium that provided
data for spontaneous lysis. Three other wells that re-
ceived 2500 targets in 100 ml R-10 and 100 ml of 1%
odium dodecyl sulfate provided data for maximal lysis.
he percentage specific lysis was calculated as [(mean
est release 2 mean spontaneous release)/(mean max-
imal wells 2 mean spontaneous release)] 3 100.
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